DE69837885D1 - Synergistische wirkung des ob/bmp morphogens und gdnf/ngf neurotropher faktoren - Google Patents

Synergistische wirkung des ob/bmp morphogens und gdnf/ngf neurotropher faktoren

Info

Publication number
DE69837885D1
DE69837885D1 DE69837885T DE69837885T DE69837885D1 DE 69837885 D1 DE69837885 D1 DE 69837885D1 DE 69837885 T DE69837885 T DE 69837885T DE 69837885 T DE69837885 T DE 69837885T DE 69837885 D1 DE69837885 D1 DE 69837885D1
Authority
DE
Germany
Prior art keywords
gdnf
cells
synergistic effect
vivo
neurotrophic factors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69837885T
Other languages
English (en)
Other versions
DE69837885T2 (de
Inventor
David C Rueger
Marc F Charette
Ted Uppsala Ebendal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Stryker Corp
Original Assignee
Curis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curis Inc filed Critical Curis Inc
Application granted granted Critical
Publication of DE69837885D1 publication Critical patent/DE69837885D1/de
Publication of DE69837885T2 publication Critical patent/DE69837885T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Hydrogenated Pyridines (AREA)
DE69837885T 1997-09-09 1998-09-09 Synergistische wirkung des ob/bmp morphogens und gdnf/ngf neurotropher faktoren Expired - Lifetime DE69837885T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5825897P 1997-09-09 1997-09-09
US58258 1997-09-09
PCT/US1998/018772 WO1999012560A1 (en) 1997-09-09 1998-09-09 Synergistic effects of op/bmp morphogens and gdnf/ngf neurotrophic factors

Publications (2)

Publication Number Publication Date
DE69837885D1 true DE69837885D1 (de) 2007-07-19
DE69837885T2 DE69837885T2 (de) 2008-02-07

Family

ID=22015678

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69837885T Expired - Lifetime DE69837885T2 (de) 1997-09-09 1998-09-09 Synergistische wirkung des ob/bmp morphogens und gdnf/ngf neurotropher faktoren

Country Status (9)

Country Link
EP (1) EP1011711B1 (de)
JP (3) JP2001515867A (de)
AT (1) ATE363914T1 (de)
AU (1) AU749454B2 (de)
CA (1) CA2303460C (de)
DE (1) DE69837885T2 (de)
ES (1) ES2288766T3 (de)
HK (1) HK1030540A1 (de)
WO (1) WO1999012560A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1011712B1 (de) 1997-09-19 2004-02-11 BIOPHARM GESELLSCHAFT ZUR BIOTECHNOLOGISCHEN ENTWICKLUNG VON PHARMAKA mbH Kombinationen von cytokine mit neurotropen aktivität
US20030170213A1 (en) * 1998-01-23 2003-09-11 Marc F. Charette Methods and compositions for enhancing cognitive function using morphogenic proteins
DE19816186A1 (de) * 1998-04-14 1999-10-21 Univ Muenchen L Maximilians GDNF-kodierende DNA, Teile davon und GDNF-Varianten
EP1159266B1 (de) 1999-03-05 2004-11-03 Duke University C-16 ungesätigte fp-selektive prostaglandin analoge
US20020013294A1 (en) 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
US20020172693A1 (en) 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
ES2618787T5 (es) 2006-04-25 2022-10-21 Univ California Administración de factores de crecimiento para el tratamiento de trastornos del SNC
JP7502882B2 (ja) 2020-03-31 2024-06-19 直樹 林田 ポリグルタミンタンパク質凝集抑制剤、及びポリグルタミン病の予防または治療用医薬

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4424996A (en) * 1994-12-14 1996-07-03 Amgen Boulder Inc. A tgf-beta superfamily type ii receptor having binding affinity
US6048964A (en) * 1995-12-12 2000-04-11 Stryker Corporation Compositions and therapeutic methods using morphogenic proteins and stimulatory factors

Also Published As

Publication number Publication date
DE69837885T2 (de) 2008-02-07
JP2001515867A (ja) 2001-09-25
CA2303460C (en) 2011-06-21
CA2303460A1 (en) 1999-03-18
ES2288766T3 (es) 2008-01-16
AU9475998A (en) 1999-03-29
JP5550673B2 (ja) 2014-07-16
JP5075877B2 (ja) 2012-11-21
EP1011711B1 (de) 2007-06-06
HK1030540A1 (en) 2001-05-11
WO1999012560A1 (en) 1999-03-18
AU749454B2 (en) 2002-06-27
JP2009209152A (ja) 2009-09-17
ATE363914T1 (de) 2007-06-15
JP2012131832A (ja) 2012-07-12
EP1011711A1 (de) 2000-06-28

Similar Documents

Publication Publication Date Title
CY1121447T1 (el) Συνθεσεις για αυξηση δραστηριοτητας τελομερασης
Zhang et al. Vascular endothelial growth factor (VEGF) expression and the effect of exogenous VEGF on survival of a random flap in the rat
GEP20063855B (en) Small organic molecule regulators of cell proliferation
BR0307871A (pt) Proteìnas contendo domìnio de folistatina
ATE381935T1 (de) Verwendung von triacetyluridin zur behandlung von mitochondrialen erkrankungen
DK0563278T3 (da) Regulering af geneekspression med ioniserende stråling
PL339745A1 (en) Agonists of apolipoprotein a-1 and their application in treating dislipidemic disorders
BR0309623A (pt) Agentes que regulam. inibem ou modulam a atividade e/ou a expressão do fator de crescimento de tecido conjuntivo (ctgf) como um único meio de diminuir a pressão intraocular e tratar retinopatias glaucomatosas/neuropatias ópticas
DE69938653D1 (de) Isolierte stromalzellen zur verwendung in der behandlung von erkrankungen des zentralnervensystems
IL138979A0 (en) Use of cannabinoids as anti-inflammatory agents
BR0112361A (pt) Métodos para tratamento de condições oculares mediadas por inflamação
DK0933995T3 (da) Fremgangsmåde til behandling af endotelskader
ATE363914T1 (de) Synergistische wirkung des ob/bmp morphogens und gdnf/ngf neurotropher faktoren
ATE258791T1 (de) Lipoxin-a4 und deren analoge zur behandlung von trockenen augen
PT862452E (pt) Formulacao de estabilizacao para o ngf
Gerhke et al. Potential of the use of an antioxidant compound to promote peripheral nerve regeneration after injury
DE69725882D1 (de) Adenovirus e4 proteine für induktion von zelltod
ES2162331T3 (es) Utilizacion del factor de crecimiento del tejido nervioso para conservacion, cultivo o tratamiento de la cornea.
BR9915951A (pt) Processo para preparação de uma composição farmacêutica para uso como um medicamento antiarritmias com um bloqueio beta adrenérgico controlado, composição farmacêutica, preparação oral e parenteral para tratamento de doenças cardìacas em mamìferos, e, método de tratamento para as mesmas
ME00533B (me) Nova primjena derivata taksoida
WO2001044294A3 (en) Compositions and methods for inhibiting endothelial cell proliferation
Sommer et al. Stressed cells survive better with light
ES2110057T3 (es) Composicion medicinal que contiene tcf-ii.
ES2154290T3 (es) Estimulacion de la diferenciacion celular por sindecano.
ATE128964T1 (de) Anwendung von beta-alethin in zellkultur und therapie.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: STRYKER CORP., KALAMAZZO, MICH., US

8328 Change in the person/name/address of the agent

Representative=s name: BOSCH JEHLE PATENTANWALTSGESELLSCHAFT MBH, 80639 M

8328 Change in the person/name/address of the agent

Representative=s name: HANNKE BITTNER & PARTNER, 93047 REGENSBURG